The use of bisphosphonates is linked to a reduced risk for fragility fractures in patients with polymyalgia rheumatica on ...

Findings showed secukinumab demonstrated statistically significant and clinically meaningful sustained remission at week 52 vs placebo. Topline data were announced from a phase 3 trial evaluating ...

The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing ...

Please provide your email address to receive an email when new articles are posted on . Patients were more likely to achieve sustained remission with sarilumab vs. placebo. The most common adverse ...

The approval was based on data from a phase 3 study which included adults with steroid-resistant active PMR who flared on at least 7.5mg per day of prednisone or equivalent during taper. The Food and ...

Tofacitinib (Xeljanz) appeared highly effective against polymyalgia rheumatica (PMR) in a small single-arm trial, researchers said, suggesting another potential alternative to long-term ...

More than half of patients with polymyalgia rheumatica have a relapse during tapering of glucocorticoid therapy. Previous studies have suggested that interleukin-6 blockade may be clinically useful in ...

THE condition that is called by the English polymyalgia rheumatica and by the French pseudopolyarthrite rhizomélique and has had many synonyms 1 is characterized by pain and stiffness in the muscles ...